MRES - InvestorNewsBreaks - Institute of Biomedical Research Corp. (MRES) Unveils Meticulously Crafted Line of Teas Sourced from Kenya
Institute of Biomedical Research (OTC: MRES) (doing business as M2Bio Sciences) is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids, medical psilocybin and mental health therapeutic research powered by artificial intelligence and evidence-based sustainable products and solutions. M2Bio Sciences today announced the forthcoming launch of a captivating line of teas sourced from the scenic gardens of Kenya. The meticulously crafted collection provides not only an exquisite sensory experience but also delivers exceptional medicinal health benefits. “We are delighted to introduce our exceptional line of purple, white and green teas from Kenya,” said Jeff Robinson, CEO of M2Bio Sciences. “Our purple tea strain has about 135 times more antioxidants* compared to a traditional black tea, so we definitely tick the box for health. In terms of addressable market, according to a report published by Vantage Market Research, the global green tea market was valued at US$13.41 billion in 2021 and is projected to reach US$26.16 billion by 2028 with a CAGR of 8.71%**. We plan to take a good chunk of that! These teas embody our commitment to providing products that promote holistic well-being. Through our partnership with the esteemed tea experts of Kenya and our team of researchers in the M2Bio Phytomedicine Labs at the University of Pretoria, we are able to offer tea enthusiasts worldwide an unparalleled combination of extraordinary taste and outstanding health benefits.”
To view the full press release, visit https://ibn.fm/DHCdy
About Institute of Biomedical Research Corp./ DBA M2Bio Sciences
Institute of Biomedical Research is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids, medical psilocybin and mental health therapeutic research powered by artificial intelligence, and evidence-based sustainable products and solutions, that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx(TM), Medspresso(TM), Liviana(TM) brands as well as artificial intelligence powered nutrition products and solutions under the M2Biome brand. In addition, its research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness and cardiovascular diseases. The company’s mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies such as artificial intelligence. The company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol MRES. For more information, visit the company’s website at www.M2Bio.co.
*Khan et al., Med Aromat Plants (Los Angeles) Purple Tea Composition and Inhibitory Effect of Anthocyanin-Rich Extract on Cancer Cell Proliferation 2018, 7:6 DOI: 10.4172/2167-0412.1000322 https://www.semanticscholar.org/paper/Purple-tea-composition-and-inhibitory-effect-of-on-Khan-Bashir/b214419bc08ee495790648719dd5d40026932fe2
**Vantage Market Research Green-Tea-Market-Size-Share-to-Surpass-26-16-Billion-by-2028-Vantage-Market-Research
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.